Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01980095 · ClinicalTrials.gov registry record · Phase 3
ERADICATE Hp - Treating Helicobacter Pylori With RHB-105
A Phase 3 study, sponsored by RedHill Biopharma Limited.
- Completed
- Registry status
- Phase 3
- Development phase
- 119
- Enrollment target
NCT01980095 is a Phase 3 study that has completed, run by RedHill Biopharma Limited. The registered enrollment target is 119 participants.
The verdict
NCT01980095, a Phase 3 study, has completed, sponsored by RedHill Biopharma Limited.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 119 participants
- Enrollment target
Study Summary
The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients.
Interventions
- DRUG Placebo
- DRUG RHB-105
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2013-11 |
| Est. Completion | 2015-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01980095
The ClinicalTrials.gov registry entry for NCT01980095 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RedHill Biopharma Limited, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01980095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01980095 about?
NCT01980095 is a clinical study titled "ERADICATE Hp - Treating Helicobacter Pylori With RHB-105". The "test and treat" strategy for treating dyspeptic patients who are H. pylori positive is rapidly becoming the standard of care. This study will test the effectiveness of RHB-105, a new triple therapy to treat H. pylori infection in dyspeptic patients.
What is the current status of trial NCT01980095?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 119 participants. The study started on 2013-11. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01980095?
The interventions under investigation include: Placebo (DRUG), RHB-105 (DRUG).
Who is sponsoring clinical trial NCT01980095?
This trial is sponsored by RedHill Biopharma Limited, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.